Dear EAP Community,
Following recent events, we are happy to provide you with clarifying information regarding the future of the EAP’s international congresses:
In the future, the EAP will host two biennial meetings:
The EAP Congres and MasterCourse
16-19 October 2025, Warsaw, Poland
This event is organized jointly with the Polish Society of Paediatrics from October 16-19 in Warsaw, Poland. Over many years, the European Academy of Paediatrics Congress and Mastercourse has gained a distinguished reputation as the event to attend to get an excellent information update, applicable to day-to-day paediatric clinical practice. Our overarching motto in 2025, “Child Health in a Changing World”
The Congress of European Paediatric Academic Societies (CEPAS)
28-31 October 2026, Lyon, France
Our brand-new paediatric conference and the successor of EAPS, organised jointly with the European Society for Paediatric Research (ESPR).
The EAP Congress and MasterCourse 2025 and CEPAS are society-led international meetings, featuring world-class scientific programmes that empower a diverse community of clinicians, researchers, nurses, allied health professionals, children, and parents. These congresses are dedicated to developing research and applying it to practical care and policy–from bench to bedside and beyond. We aim to unite paediatric professionals to advance child health through innovative research, education, and collaboration–beyond purely commercial interests.
Yours Sincerely,
Prof. Berthold Koletzko
President
European Academy of Paediatrics
Prof. Teresa Jacowska
President
Polish Society of Paediatrics
Dr. Lukasz Dembinski
Treasurer, EAP/EBP Treasurer
EAP Congress & MasterCourse
Chair, Scientific Committee
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.